Expression of estrogen receptor alpha with a Tet-off adenoviral system induces G0/G1 cell cycle arrest in SKBr3 breast cancer cells

International Journal of Oncology

Volumn 36, Issue 2, 2010, Pages 451-458

  Peng, Jing ^a   Jordan, V Craig ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

ER negative breast cancer; Estrogen receptor; Growth factor receptor; SKBr3 cells; Tet off adenoviral system

Indexed keywords

ADENOVIRUS VECTOR; CYCLIN DEPENDENT KINASE INHIBITOR 1; DOXYCYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; RETINOBLASTOMA PROTEIN; TET OFF ADENOVIRUS VECTOR; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; E2F1 TRANSCRIPTION FACTOR; ESTROGEN RECEPTOR ALPHA; ESTROGENS; FEMALE; GENETIC VECTORS; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TETRACYCLINE RESISTANCE;

EID: 75449112004     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo-00000519     Document Type: Article

References (30)

1. Jordan VC: A century of deciphering the control mechanisms of sex steroid action in breast and prostate cancer: the origins of targeted therapy and chemoprevention. Cancer Res 69: 1243-1254, 2009.
2. Wolf DM and Jordan VC: A laboratory model to explain the survival advantage observed in patients taking adjuvant tamoxifen therapy. Recent Results Cancer Res 127: 23-33, 1993.
3. Song RX, Mor G, Naftolin F, et al: Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol. J Natl Cancer Inst 93: 1714-1723, 2001.
4. Lewis JS, Osipo C, Meeke K and Jordan VC: Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawal. J Steroid Biochem Mol Biol 94: 131-141, 2005.
5. Lewis JS, Meeke K, Osipo C, et al: Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. J Natl Cancer Inst 97: 1746-1759, 2005.
6. Yao K, Lee ES, Bentrem DJ, et al: Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin Cancer Res 6: 2028-2036, 2000.
7. Jordan VC: The 38th David A. Karnofsky lecture: the paradoxical actions of estrogen in breast cancer - urvival or death? J Clin Oncol 26: 3073-3082, 2008.
8. Brinkman JA and El-Ashry D: ER re-expression and re-sensitization to endocrine therapies in ER-negative breast cancers. J Mammary Gland Biol Neoplasia 14: 67-78, 2009.
9. Bayliss J, Hilger A, Vishnu P, Diehl K and El-Ashry D: Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response. Clin Cancer Res 13: 7029-7036, 2007.
10. Jiang SY and Jordan VC: Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor. J Natl Cancer Inst 84: 580-591, 1992.
11. Levenson AS and Jordan VC: Transfection of human estrogen receptor (ER) cDNA into ER-negative mammalian cell lines. J Steroid Biochem Mol Biol 51: 229-239, 1994.
12. Stender JD, Frasor J, Komm B, Chang KCN, Kraus WL and Katzenellenbogen BS: Estrogen-regulated gene networks in human breast cancer cells: involvement of E2F1 in the regulation of cell proliferation. Mol Endocrinol 21: 2112-2123, 2007.
13. Lazennec G, Alcorn JL and Katzenellenbogen BS: Adenovirus-mediated delivery of a dominant negative estrogen receptor gene abrogates estrogen-stimulated gene expression and breast cancer cell proliferation. Mol Endocrinol 13: 969-980, 1999.
14. Lazennec G and Katzenellenbogen BS: Expression of human estrogen receptor using an efficient adenoviral gene delivery system is able to restore hormone-dependent features to estrogen receptor-negative breast carcinoma cells. Mol Cell Endocrinol 149: 93-105, 1999.
15. Arpino G, Wiechmann L, Osborne CK and Schiff R: Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 29: 217-233, 2008.
16. Liu H, Cheng D, Weichel AK, et al: Cooperative effect of gefitinib and fumitremorgin c on cell growth and chemo-sensitivity in estrogen receptor alpha negative fulvestrant-resistant MCF-7 cells. Int J Oncol 29: 1237-1246, 2006.
17. Murphy CS, Pink JJ and Jordan VC: Characterization of a receptor-negative, hormone-nonresponsive clone derived from a T47D human breast cancer cell line kept under estrogen-free conditions. Cancer Res 50: 7285-7292, 1990.
18. Pink JJ, Bilimoria MM, Assikis J and Jordan VC: Irreversible loss of the oestrogen receptor in T47D breast cancer cells following prolonged oestrogen deprivation. Br J Cancer 74: 1227-1236, 1996.
19. Ariazi EA, Kraus RJ, Farrell ML, Jordan VC and Mertz JE: Estrogen-related receptor alpha1 transcriptional activities are regulated in part via the ErbB2/HER2 signaling pathway. Mol Cancer Res 5: 71-85, 2007.
20. Broude EV, Swift ME, Vivo C, et al: p21(Waf1/Cip1/Sdi1) mediates retinoblastoma protein degradation. Oncogene 26: 6954-6958, 2007.
21. Schiff R, Massarweh SA, Shou J, et al: Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators. Cancer Chemother Pharmacol 56 (Suppl. 1): 10-20, 2005.
22. Huang HJ, Neven P, Drijkoningen M, et al: Hormone receptors do not predict the HER2/neu status in all age groups of women with an operable breast cancer. Ann Oncol 16: 1755-1761, 2005.
23. Read LD, Keith D Jr, Slamon DJ and Katzenellenbogen BS: Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines. Cancer Res 50: 3947-3951, 1990.
24. Senzer N and Nemunaitis J: A review of contusugene ladenovec (Advexin) p53 therapy. Curr Opin Mol Ther 11: 54-61, 2009.
25. Patil SD, Rhodes DG and Burgess DJ: DNA-based therapeutics and DNA delivery systems: a comprehensive review. AAPS J 7: E61-E77, 2005.
26. De Gregori J and Johnson DG: Distinct and overlapping roles for E2F family members in transcription, proliferation and apoptosis. Curr Mol Med 6: 739-748, 2006.
27. Vuaroqueaux V, Urban P, Labuhn M, et al: Low E2F1 transcript levels are a strong determinant of favorable breast cancer outcome. Breast Cancer Res 9: R33, 2007.
28. Baldini E, Camerini A, Sgambato A, et al: Cyclin A and E2F1 overexpression correlate with reduced disease-free survival in node-negative breast cancer patients. Anticancer Res 26: 4415-4421, 2006.
29. Han S, Park K, Bae BN, et al: E2F1 expression is related with the poor survival of lymph node-positive breast cancer patients treated with fluorouracil, doxorubicin and cyclophosphamide. Breast Cancer Res Treat 82: 11-16, 2003.
30. Zhang SY, Liu SC, Al-Saleem LF, et al: E2F-1: a proliferative marker of breast neoplasia. Cancer Epidemiol Biomarkers Prev 9: 395-401, 2000.